Brief: 60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation For Acute Babesiosis Treatment
11/06/2024 13:14
June 11 (Reuters) - 60 Degrees Pharmaceuticals Inc
SXTP.O :
* 60 DEGREES PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG
DESIGNATION
FOR TAFENOQUINE FOR TREATMENT OF PATIENTS WITH ACUTE BABESIOSIS
Source text for Eikon: ID:nGNX6g42Qf
Further company coverage: SXTP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 60 Degrees Pharmaceuticals
See all newsBrief: 60 Degrees Pharmaceuticals Says May Submit NDA For Tafenoquine To FDA Before End Of Q1 2028 - SEC Filing
U.S. RESEARCH ROUNDUP-Analog Devices, Intuit, NVIDIA
Brief: 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (Ndin) With FDA For Australian Chestnut Extract
NASDAQ RESUMED AT 10:06 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:55 AM